Q+A: Ran Reshef, MD, on the Promise of Car T-Cell Therapy

Recently, Dr. Ran Reshef, director of the CAR T-cell program at the HICCC, had a Q+A on a promising type of treatment called chimeric antigen receptor (CAR) T-cell therapy, which re-engineers a patient's white blood cells to recognize and kill tumor cells.

Read the full Q+A with Ran Reshef, MD on cancer.columbia.edu